BUSINESS WIRE: Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics …

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

o Launch expected in April 2013

PARIS & MONTREAL --(BUSINESS WIRE)-- 09.04.2013 --

Regulatory News:

Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013.

Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen's group, stated: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysportwill now be available in Canada for the treatment of glabellar lines."

About Dysport

The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of muscular spasticity, including cervical dystonia (or spasmodic torticollis, a chronic condition in which the neck is twisted or deviated), spasticity of the upper/lower part of the body in adults after a stroke, dynamic equinus foot deformity in children with cerebral palsy, blepharospasm (involuntary contraction of the eyelids) and hemifacial spasm (involuntary contraction of the muscles located on one side of the face). Dysport was later developed for the treatment of a wide variety of neuromuscular disorders, as well as for use in aesthetic medicine. On 31 December 2012, Dysport had marketing authorizations in force in 75 countries. In Canada, Dysport has been approved for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age since June 12th, 2012.

About the agreement with Valeant

In March 2006, the Ipsen Group signed an agreement with the Medicis Group (USA) granting the latter the exclusive right to develop, sell and market certain formulations of botulinum toxin type A for use in aesthetic medicine indications approved in the United States and Canada. On December 11th, 2012, Medicis was acquired by Valeant, who has succeeded Medicis in its rights of Dysport in North America.

Visit link:

BUSINESS WIRE: Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics ...